NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Michigan State University Research on Postoperative Pain Management and Healing
TL;DR
Michigan State University research reveals suppressing post-op inflammation may cause chronic pain, offering companies like Soligenix Inc. opportunities to develop targeted anti-inflammatory therapies.
Michigan State University research suggests anti-inflammatory medications after surgery might prolong pain by interfering with natural healing processes, potentially leading to chronic conditions.
This research could lead to better pain management protocols, reducing long-term suffering for surgical patients and improving overall recovery outcomes.
New research challenges conventional post-surgery pain management, suggesting inflammation might be necessary for proper healing rather than something to always suppress.
Found this article helpful?
Share it with your network and spread the knowledge!
The research suggests that suppressing postoperative inflammation with anti-inflammatory medications could be counterproductive, potentially delaying healing and contributing to chronic pain that lasts for years after surgery.
It challenges the normal practice of administering anti-inflammatory medications after surgery and may explain why some patients develop chronic pain, potentially leading to changes in postoperative care protocols.
The normal practice has been to administer anti-inflammatory medications to manage postoperative pain and inflammation.
The research was conducted at Michigan State University, and more information can be found through the MSU Today article.
Soligenix Inc. (NASDAQ: SNGX) is mentioned as being involved in research aimed at developing therapies against inflammation.
This content was published by BioMedWire (BMW), a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences developments.
The research suggests that more insights are needed on when it is prudent to block the inflammation process, which could lead to more targeted approaches to postoperative pain management.
You can visit https://www.BioMedWire.com or contact them at Editor@BioMedWire.com or 415.949.5050 for more information about their communications platform and services.
BioMedWire provides specialized communications in the biotech sector and is part of the Dynamic Brand Portfolio @ IBN, with full terms of use and disclaimers available on their website.
Curated from InvestorBrandNetwork (IBN)
